Wednesday, July 8, 2026

pharma · IgA Nephropathy · Rhematoid Arthritis · JBIO

Jade Biosciences

Jade Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker JBIO. Primary therapeutic focus areas include IgA Nephropathy, Rhematoid Arthritis. NovaPharmaNews links 4 clinical

Waltham, USA HQ
2024 Founded
72 Employees
Public company Type
JBIO · NYSE Ticker
Company details
Status
Public
HQ
Waltham, USA
Founded
2024
Employees
72
Programs
4
Drugs
1
Patents
2
Clinical program

JADE101

Phase 1 · small molecule · Healthy Volunteers (HV)

JADE101 for Healthy Volunteers (HV) is a Phase 1 program (small_molecule) at Jade Biosciences with 1 ClinicalTrials.gov record(s).

← All Jade Biosciences projects Phase 1 small molecule active

Internal code JADE101-05

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Jade Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers (HV)
Status
active
Trials
1

Clinical trials